What is HC Wainwright’s Estimate for MediWound Q1 Earnings?

MediWound Ltd. (NASDAQ:MDWD) – Research analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of MediWound in a research note issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, down from their prior forecast of ($0.56). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound’s Q2 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($1.98) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at $0.80 EPS.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The firm had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the previous year, the business earned ($0.19) earnings per share.

Several other research analysts also recently commented on MDWD. Craig Hallum started coverage on shares of MediWound in a research note on Friday, February 28th. They issued a “buy” rating and a $39.00 target price on the stock. StockNews.com raised shares of MediWound to a “sell” rating in a research note on Friday, March 21st.

MediWound Stock Performance

Shares of MDWD stock opened at $16.66 on Monday. The company has a market capitalization of $179.81 million, a P/E ratio of -5.74 and a beta of 0.82. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The stock has a 50 day moving average price of $18.08 and a two-hundred day moving average price of $17.59.

Institutional Trading of MediWound

Large investors have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC bought a new position in MediWound in the 3rd quarter worth $89,000. Investor AB bought a new position in MediWound in the third quarter worth about $15,750,000. Point72 Asset Management L.P. purchased a new stake in MediWound in the third quarter worth about $212,000. State Street Corp boosted its position in MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 45,529 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 8,449 shares during the period. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.